



🖌 Xacobeo 21·22





CiQUS Lecture



Thursday, **June 8**, 2023 12:15 p.m. - CiQUS Seminar Room

Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, F-75005 Paris, France.

Research Group website: <u>www.gassergroup.com</u> Phone: +33 1 85 78 41 51 Email: <u>gilles.gasser@chimieparistech.psl.eu</u>

Abstract:

Metal complexes are currently playing a tremendous role in medicine.¹ For example, the platinum complex cisplatin and its derivatives oxaliplatin and carboplatin are employed in more than 50% of the treatment regimes for patients suffering from cancer!

Over the last years, our research group focused its attention on the development of novel metal complexes as imaging and therapeutic agents against cancer and parasitic diseases.²⁻⁹ During this talk, we will present our latest results, including in vivo results, on these topics.

References

(1) Boros, E.; Dyson, P. J.; Gasser , G. Classification of Metal-based Drugs According to Their Mechanisms of Action. Chem 2020, *6*, 41-60.

(2) Brandt, M.; Cardinale, J.; Aulsebrook, M. L.; Gasser, G.; Mindt, T. L. An Overview on PET Radiochemistry: Part 2 - Radiometals J. Nucl. Med. 2018, 59, 1500-1506.

(3) Gourdon, L.; Cariou, K.; Gasser, G. Phototherapeutic anticancer strategies with first-row transition metal complexes: a critical review. Chem. Soc. Rev. 2022, 51, 1167-1195.









(4) Heinemann, F. W.; Karges, J.; Gasser , G. Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy. Acc. Chem. Res. 2017, 50, 2727-2736

(5) Martínez-Alonso, M.; Gasser, G. Ruthenium polypyridyl complex-containing bioconjugates. Coord. Chem. Rev. 2021, 434, 213736.

(6) Notaro, A.; Gasser , G. Monomeric and Dimeric Coordinatively Saturated and Substitutionally Inert Ru(II) Polypyridyl Complexes as Anticancer Drug Candidates. Chem. Soc. Rev. 2017, 46, 7317-7337.

(7) Ong, Y. C.; Roy, S.; Andrews, P. C.; Gasser, G. Metal Compounds against Neglected Tropical Diseases. Chem. Rev. 2019, 119, 730-796.

(8) Patra, M.; Gasser, G. The Medicinal Chemistry of Ferrocene and its Derivatives. Nature Rev. Chem. 2017, 1, 0066, and references therein.

(9) Patra, M.; Zarschler, K.; Pietzsch, H.-J.; Stephan, H.; Gasser, G. New insights into the pretargeting approach to image and treat tumours. Chem. Soc. Rev. 2016, 45, 6415-6431.

Biosketch:

Gilles Gasser was born, raised and educated in the French-speaking part of Switzerland. After a PhD thesis in supramolecular chemistry with Prof. Helen Stoeckli-Evans (University of Neuchâtel, Switzerland), Gilles undertook two post-docs, first with the late Prof. Leone Spiccia (Monash University, Australia) in bioinorganic chemisty and then as an Alexander von Humboldt fellow with Prof. Nils Metzler Nolte (Ruhr-University Bochum, Germany) in bioorganometallic chemistry. In 2010, Gilles started his independent scientific career at the University of Zurich as a Swiss National Science Foundation (SNSF) Ambizione Fellow before obtaining a SNSF Assistant Professorship in 2011. In 2016, Gilles moved to Chimie ParisTech, PSL University (Paris, France) to take a PSL Chair of Excellence. Gilles is a RSC Fellow recipient and was the recipient of several fellowships and awards including the Alfred Werner Award from the Swiss Chemical Society, an ERC Consolidator Grant and Proof of Concept, the Thieme Chemistry Journal Award, the Jucker Award for his contribution to cancer research, the European BioInorganic Chemistry (EuroBIC) medal and recently the Pierre Fabre Award for therapeutic innovation from the Société de Chimie Thérapeutique (SCT). He was elected an Overseas Fellow of the Churchill College, University of Cambridge in 2022. Gilles' research interests lay in the use of metal complexes in different areas of medicinal and biological chemistry.